Article Information
PubMed
Published By
History
- Received June 12, 2020
- Revision received September 25, 2020
- Accepted October 19, 2020
- Published online November 24, 2020.
Copyright & Usage
Copyright © 2020 Patel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Author Information
- Sejal Patel1,
- Derek Howard1,
- Alana Man1,2,
- Deborah Schwartz3,4,
- Joelle Jee1,5,
- Daniel Felsky1,
- Zdenka Pausova6,
- Tomas Paus4,7,8 and
- Leon French1,7,8,9
- 1Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health, Toronto, Ontario M5T 1L8, Canada
- 2Victoria College, University of Toronto, Toronto, Ontario M5S 1K7, Canada
- 3Rotman Research Institute, Baycrest Centre for Geriatric Care, University of Toronto, Toronto, Ontario M6A 2E1, Canada
- 4Department of Psychology, University of Toronto, Toronto, Ontario M5S 3G3, Canada
- 5Faculty of Arts and Science, University of Toronto, Toronto, Ontario M5S 3G3, Canada
- 6The Hospital for Sick Children, University of Toronto, Toronto, Ontario M5G 1X8, Canada
- 7Department of Psychiatry, University of Toronto, Ontario M5S 3G3, Toronto
- 8Institute for Medical Science, University of Toronto, Toronto, Ontario M5S 1A8, Canada
- 9Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario M5T 1L8, Canada
- Correspondence should be addressed to Leon French at leonfrench{at}gmail.com.
Author contributions
Author contributions: S.P., D.H., D.S., Z.P., T.P., and L.F. designed research; S.P., D.H., A.M., D.S., J.J., Z.P., T.P., and L.F. performed research; S.P., D.H., A.M., D.S., J.J., Z.P., T.P., and L.F. contributed unpublished reagents/analytic tools; S.P., D.H., A.M., D.S., J.J., D.F., Z.P., T.P., and L.F. analyzed data; S.P., D.H., D.F., T.P., and L.F. wrote the paper.
Disclosures
L.F. owns shares in Cortexyme Inc., a company that is developing a gingipain inhibitor to treat Alzheimer's Disease. All other authors declare no competing financial interests.
This work was supported by the CAMH Foundation, CAMH Discovery Fund, and a National Science and Engineering Research Council of Canada (NSERC) Discovery Grant (L.F.).
Funding
CAMH Discovery Fund
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (NSERC)
CAMH Foundation
Other Version
- You are viewing the most recent version of this article.
- previous version (November 24, 2020).
Online Impact
Article usage
In this issue
Donor-Specific Transcriptomic Analysis of Alzheimer's Disease-Associated Hypometabolism Highlights a Unique Donor, Ribosomal Proteins and Microglia
